Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
M-002
- Development stage
- Preclinical
- Lead developer
- MGFB Biopharma
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intravenous, Intramuscular
01
Overview
M-002 is an experimental therapeutic vaccine in preclinical development for the treatment of glioma. Developed by MGFB Bio, a subsidiary of Greenfire Bio (formerly FairWinds Bio), the vaccine utilizes the proprietary Heteroclitic Epitope Activated Therapy (HEAT) platform. This technology, originally developed by Professor Richard Vile at the Mayo Clinic, is designed to elicit robust anti-tumor immune responses while specifically addressing challenges common to solid tumors, such as immune escape, tumor resistance, and low mutational burden. MGFB Bio was formed through a patent license agreement with the Mayo Clinic, with founding equity shared among FairWinds Bio, the University of Leeds, and the Mayo Clinic.
- Other names
- HEAT vaccine
Beyond the preview
Go deeper on M-002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on M-002.